MOTS-c Metabolic Regulation
Mechanisms by which MOTS-c influences glucose and lipid metabolism.
MOTS-c Origin and Discovery
MOTS-c is a peptide encoded in mitochondrial DNA and studied almost entirely in cells and mice. Our MOTS-c overview covers the rest.
Mitochondrial-Derived Peptide
| Feature | Description |
|---|---|
| Origin | Mitochondrial genome (12S rRNA) |
| Size | 16 amino acids |
| Discovery | 2015 |
| Classification | Mitochondrial-derived peptide |
Metabolic Mechanisms
AMPK Pathway
In the 2015 discovery study, MOTS-c blocked the folate cycle in cultured cells. AICAR built up more than 20-fold and activated AMPK, the cell's energy sensor.
| Step | Event | Metabolic Effect |
|---|---|---|
| 1 | Folate cycle inhibited | Purine synthesis stalls |
| 2 | AICAR accumulates | AMPK activation |
| 3 | ACC inactivated | Fat oxidation favored |
| 4 | GLUT4 rises (mouse muscle) | Glucose uptake increased |
Nuclear Translocation Under Stress
In a 2018 cell study, glucose restriction sent MOTS-c into the nucleus, via AMPK, to regulate antioxidant-response genes. A 2020 study of human muscle didn't find that antioxidant-gene link.
Glucose Metabolism
| Effect | Mechanism | Evidence |
|---|---|---|
| Increased uptake | AMPK activation, more GLUT4 | Cells and mice |
| Improved sensitivity | Acts mainly on skeletal muscle | Mice (aging and high-fat diet) |
Lipid Metabolism
| Effect | Mechanism | Evidence |
|---|---|---|
| Fat oxidation | ACC inactivation, more CPT1 | Cell culture |
| Lipogenesis reduction | Proposed | Less liver fat (high-fat-diet mice) |
| Adipose browning | Thermogenic genes | Cold-exposed mice |
Age-Related Changes
MOTS-c falls with age in mice. In healthy men, plasma levels were lower in older groups but muscle levels were higher.
| Age Group | Plasma MOTS-c | Muscle MOTS-c |
|---|---|---|
| Young (18-30) | Higher | Lower |
| Middle-aged and older (45-81) | Lower | About 1.5x young |
Therapeutic Potential
As of October 2026, no published study has given MOTS-c to people. The analog CB4211 lowered liver enzymes, not liver fat, versus placebo in a 4-week trial of 20 adults with fatty liver. CohBar's 2023 liquidation ended it.
Exercise Synergy
Exercise raises the body's own MOTS-c, but no human study has combined the two. See exercise mimetic effects and MOTS-c and endurance.
Current Research Status
| Aspect | Status |
|---|---|
| Animal efficacy | Shown in mice |
| Human trials | None published as of October 2026 |
| Optimal dosing | Unknown |
As of October 2026, WADA's 2026 Prohibited List names MOTS-c under S4.4.1 (non-Specified). The one Phase 2 registry entry (NCT07505745) has a disputed sponsor.
What We Still Don't Know
Nobody has shown the AICAR-AMPK chain in human muscle, or explained why plasma and muscle levels diverge with age.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
- MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress (Cell Metabolism, 2018)
- MOTS-c increases adipose thermogenic activation to promote cold adaptation in mice (International Journal of Molecular Sciences, 2019)
- Plasma and skeletal muscle MOTS-c in healthy aging men (Aging, 2020)
- MOTS-c is an exercise-induced regulator of age-dependent physical decline (Nature Communications, 2021)
- CohBar topline results of the CB4211 Phase 1a/1b study (SEC filing, 2021)
- CohBar 8-K on liquidation and dissolution (SEC filing, November 2023)
- NCT07505745: MOTS-c Phase 2a registry entry (ClinicalTrials.gov, accessed October 2026)
- Vendor review of MOTS-c registry records, including the disputed NCT07505745 sponsor (Curo, vendor page, 2026)
- World Anti-Doping Code 2026 Prohibited List (WADA, 2025)